# Evolution of beta-lactam resistance causes fitness reductions and several cases of collateral sensitivities in the human pathogen Haemophilus influenzae

## TL;DR

This study shows how Haemophilus influenzae evolves resistance to beta-lactam antibiotics, often leading to reduced fitness and unexpected sensitivities to other drugs.

## Contribution

The study reveals that resistance evolution in H. influenzae leads to unpredictable phenotypes and collateral sensitivities.

## Key findings

- Resistance to beta-lactam antibiotics was driven by mutations in ftsI and OmpP2 genes.
- Over 50% of resistant clones became more susceptible to aminoglycosides, clarithromycin, and colistin.
- Some mutations caused cross-resistance to meropenem and fluoroquinolones.

## Abstract

The evolution of antimicrobial-resistant pathogens poses a global health threat, and it is unclear if evolutionary trajectories to resistance lead to predictable phenotypes. We analyzed antimicrobial resistance (AMR) evolution in the human pathogen Haemophilus influenzae in controlled evolution experiments with increasing concentrations of either ampicillin, cefotaxime, or ceftriaxone. We isolated 315 clones from different time points of six independent experiments and characterized changes in genome sequences, bacterial fitness, and minimum inhibitory concentrations (MICs) to 14 antibiotics. Resistance evolution under ampicillin and cefotaxime was mainly driven by mutations in the ftsI gene, encoding the penicillin-binding protein 3. However, ceftriaxone exposure repeatedly selected for amino acid substitutions in the outer membrane protein P2 (OmpP2). Some OmpP2 mutants reproducibly showed phenotypic heterogeneity not only for ceftriaxone but also for fluoroquinolones, rifampicin, and tetracycline. Bacterial fitness assessments revealed trade-offs between resistance-associated mutations and growth, though no systematic correlation of MIC increase and growth deficit was detected. Over 50% of the selected clones became more susceptible to aminoglycosides, clarithromycin, and colistin, while some mutation patterns resulted in cross-resistance to meropenem and fluoroquinolones. Overall, beta-lactam antibiotics reproducibly selected mutants with increased MICs, but evolutionary pathways and resulting phenotypes remain unpredictable. These findings highlight the complexity of resistance evolution and suggest that future AMR treatment strategies may need to consider strain-specific and collateral effects more closely.